Skip to main content
Top
Published in: BMC Psychiatry 1/2024

Open Access 01-12-2024 | Schizophrenia | Research

Asparagine reduces the risk of schizophrenia: a bidirectional two-sample mendelian randomization study of aspartate, asparagine and schizophrenia

Authors: Huang-Hui Liu, Yao Gao, Dan Xu, Xin-Zhe Du, Si-Meng Wei, Jian-Zhen Hu, Yong Xu, Liu Sha

Published in: BMC Psychiatry | Issue 1/2024

Login to get access

Abstract

Background

Despite ongoing research, the underlying causes of schizophrenia remain unclear. Aspartate and asparagine, essential amino acids, have been linked to schizophrenia in recent studies, but their causal relationship is still unclear. This study used a bidirectional two-sample Mendelian randomization (MR) method to explore the causal relationship between aspartate and asparagine with schizophrenia.

Methods

This study employed summary data from genome-wide association studies (GWAS) conducted on European populations to examine the correlation between aspartate and asparagine with schizophrenia. In order to investigate the causal effects of aspartate and asparagine on schizophrenia, this study conducted a two-sample bidirectional MR analysis using genetic factors as instrumental variables.

Results

No causal relationship was found between aspartate and schizophrenia, with an odds ratio (OR) of 1.221 (95%CI: 0.483–3.088, P-value = 0.674). Reverse MR analysis also indicated that no causal effects were found between schizophrenia and aspartate, with an OR of 0.999 (95%CI: 0.987–1.010, P-value = 0.841). There is a negative causal relationship between asparagine and schizophrenia, with an OR of 0.485 (95%CI: 0.262-0.900, P-value = 0.020). Reverse MR analysis indicates that there is no causal effect between schizophrenia and asparagine, with an OR of 1.005(95%CI: 0.999–1.011, P-value = 0.132).

Conclusion

This study suggests that there may be a potential risk reduction for schizophrenia with increased levels of asparagine, while also indicating the absence of a causal link between elevated or diminished levels of asparagine in individuals diagnosed with schizophrenia. There is no potential causal relationship between aspartate and schizophrenia, whether prospective or reverse MR. However, it is important to note that these associations necessitate additional research for further validation.
Literature
1.
go back to reference Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–203.CrossRefPubMedPubMedCentral Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–203.CrossRefPubMedPubMedCentral
2.
go back to reference Rehm J, Shield KD. Global burden of disease and the impact of mental and addictive disorders. Curr Psychiatry Rep. 2019;21(2):10.CrossRefPubMed Rehm J, Shield KD. Global burden of disease and the impact of mental and addictive disorders. Curr Psychiatry Rep. 2019;21(2):10.CrossRefPubMed
3.
go back to reference Vita A, Minelli A, Barlati S, Deste G, Giacopuzzi E, Valsecchi P, Turrina C, Gennarelli M. Treatment-resistant Schizophrenia: genetic and neuroimaging correlates. Front Pharmacol. 2019;10:402.CrossRefPubMedPubMedCentral Vita A, Minelli A, Barlati S, Deste G, Giacopuzzi E, Valsecchi P, Turrina C, Gennarelli M. Treatment-resistant Schizophrenia: genetic and neuroimaging correlates. Front Pharmacol. 2019;10:402.CrossRefPubMedPubMedCentral
5.
go back to reference Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7.
6.
go back to reference Abdulbagi M, Wang L, Siddig O, Di B, Li B. D-Amino acids and D-amino acid-containing peptides: potential disease biomarkers and therapeutic targets? Biomolecules. 2021;11(11):1716.CrossRefPubMedPubMedCentral Abdulbagi M, Wang L, Siddig O, Di B, Li B. D-Amino acids and D-amino acid-containing peptides: potential disease biomarkers and therapeutic targets? Biomolecules. 2021;11(11):1716.CrossRefPubMedPubMedCentral
7.
go back to reference Krashia P, Ledonne A, Nobili A, Cordella A, Errico F, Usiello A, D’Amelio M, Mercuri NB, Guatteo E, Carunchio I. Persistent elevation of D-Aspartate enhances NMDA receptor-mediated responses in mouse substantia Nigra pars compacta dopamine neurons. Neuropharmacology. 2016;103:69–78.CrossRefPubMed Krashia P, Ledonne A, Nobili A, Cordella A, Errico F, Usiello A, D’Amelio M, Mercuri NB, Guatteo E, Carunchio I. Persistent elevation of D-Aspartate enhances NMDA receptor-mediated responses in mouse substantia Nigra pars compacta dopamine neurons. Neuropharmacology. 2016;103:69–78.CrossRefPubMed
8.
go back to reference Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, Petkova E, Silipo G, Javitt DC. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: correlation with symptoms. Schizophr Res. 2018;191:70–9.CrossRefPubMed Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, Petkova E, Silipo G, Javitt DC. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: correlation with symptoms. Schizophr Res. 2018;191:70–9.CrossRefPubMed
9.
go back to reference Elkis H, Buckley PF. Treatment-resistant Schizophrenia. Psychiatr Clin North Am. 2016;39(2):239–65.CrossRefPubMed Elkis H, Buckley PF. Treatment-resistant Schizophrenia. Psychiatr Clin North Am. 2016;39(2):239–65.CrossRefPubMed
10.
go back to reference Dunlop DS, Neidle A, McHale D, Dunlop DM, Lajtha A. The presence of free D-aspartic acid in rodents and man. Biochem Biophys Res Commun. 1986;141(1):27–32.CrossRefPubMed Dunlop DS, Neidle A, McHale D, Dunlop DM, Lajtha A. The presence of free D-aspartic acid in rodents and man. Biochem Biophys Res Commun. 1986;141(1):27–32.CrossRefPubMed
11.
go back to reference de Bartolomeis A, Vellucci L, Austin MC, De Simone G, Barone A. Rational and translational implications of D-Amino acids for treatment-resistant Schizophrenia: from neurobiology to the clinics. Biomolecules. 2022;12(7):909.CrossRefPubMedPubMedCentral de Bartolomeis A, Vellucci L, Austin MC, De Simone G, Barone A. Rational and translational implications of D-Amino acids for treatment-resistant Schizophrenia: from neurobiology to the clinics. Biomolecules. 2022;12(7):909.CrossRefPubMedPubMedCentral
13.
go back to reference Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25(10):859–85.CrossRefPubMed Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25(10):859–85.CrossRefPubMed
14.
go back to reference Errico F, Napolitano F, Squillace M, Vitucci D, Blasi G, de Bartolomeis A, Bertolino A, D’Aniello A, Usiello A. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. J Psychiatr Res. 2013;47(10):1432–7.CrossRefPubMed Errico F, Napolitano F, Squillace M, Vitucci D, Blasi G, de Bartolomeis A, Bertolino A, D’Aniello A, Usiello A. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. J Psychiatr Res. 2013;47(10):1432–7.CrossRefPubMed
15.
go back to reference Rousseau J, Gagné V, Labuda M, Beaubois C, Sinnett D, Laverdière C, Moghrabi A, Sallan SE, Silverman LB, Neuberg D, et al. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood. 2011;118(22):5883–90.CrossRefPubMedPubMedCentral Rousseau J, Gagné V, Labuda M, Beaubois C, Sinnett D, Laverdière C, Moghrabi A, Sallan SE, Silverman LB, Neuberg D, et al. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood. 2011;118(22):5883–90.CrossRefPubMedPubMedCentral
16.
go back to reference Liu L, Zhao J, Chen Y, Feng R. Metabolomics strategy assisted by transcriptomics analysis to identify biomarkers associated with schizophrenia. Anal Chim Acta. 2020;1140:18–29.CrossRefPubMed Liu L, Zhao J, Chen Y, Feng R. Metabolomics strategy assisted by transcriptomics analysis to identify biomarkers associated with schizophrenia. Anal Chim Acta. 2020;1140:18–29.CrossRefPubMed
17.
go back to reference Cao B, Wang D, Brietzke E, McIntyre RS, Pan Z, Cha D, Rosenblat JD, Zuckerman H, Liu Y, Xie Q, et al. Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study. Amino Acids. 2018;50(8):1013–23.CrossRefPubMed Cao B, Wang D, Brietzke E, McIntyre RS, Pan Z, Cha D, Rosenblat JD, Zuckerman H, Liu Y, Xie Q, et al. Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study. Amino Acids. 2018;50(8):1013–23.CrossRefPubMed
18.
go back to reference Olthof BMJ, Gartside SE, Rees A. Puncta of neuronal nitric oxide synthase (nNOS) mediate NMDA receptor signaling in the Auditory Midbrain. J Neuroscience: Official J Soc Neurosci. 2019;39(5):876–87.CrossRef Olthof BMJ, Gartside SE, Rees A. Puncta of neuronal nitric oxide synthase (nNOS) mediate NMDA receptor signaling in the Auditory Midbrain. J Neuroscience: Official J Soc Neurosci. 2019;39(5):876–87.CrossRef
19.
go back to reference Tortorella A, Monteleone P, Fabrazzo M, Viggiano A, De Luca L, Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology. 2001;44(4):167–71.CrossRefPubMed Tortorella A, Monteleone P, Fabrazzo M, Viggiano A, De Luca L, Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology. 2001;44(4):167–71.CrossRefPubMed
20.
go back to reference Rao ML, Strebel B, Gross G, Huber G. Serum amino acid profiles and dopamine in schizophrenic patients and healthy subjects: window to the brain? Amino Acids. 1992;2(1–2):111–8.CrossRefPubMed Rao ML, Strebel B, Gross G, Huber G. Serum amino acid profiles and dopamine in schizophrenic patients and healthy subjects: window to the brain? Amino Acids. 1992;2(1–2):111–8.CrossRefPubMed
21.
go back to reference Davey Smith G, Ebrahim S. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ (Clinical Res ed). 2005;330(7499):1076–9.CrossRef Davey Smith G, Ebrahim S. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ (Clinical Res ed). 2005;330(7499):1076–9.CrossRef
22.
go back to reference Freuer D, Meisinger C. Causal link between thyroid function and schizophrenia: a two-sample mendelian randomization study. Eur J Epidemiol. 2023;38(10):1081–8.CrossRefPubMedPubMedCentral Freuer D, Meisinger C. Causal link between thyroid function and schizophrenia: a two-sample mendelian randomization study. Eur J Epidemiol. 2023;38(10):1081–8.CrossRefPubMedPubMedCentral
23.
go back to reference Papiol S, Schmitt A, Maurus I, Rossner MJ, Schulze TG, Falkai P. Association between Physical Activity and Schizophrenia: results of a 2-Sample mendelian randomization analysis. JAMA Psychiat. 2021;78(4):441–4.CrossRef Papiol S, Schmitt A, Maurus I, Rossner MJ, Schulze TG, Falkai P. Association between Physical Activity and Schizophrenia: results of a 2-Sample mendelian randomization analysis. JAMA Psychiat. 2021;78(4):441–4.CrossRef
24.
go back to reference Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, Arnold M, Erte I, Forgetta V, Yang TP, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014;46(6):543–50.CrossRefPubMedPubMedCentral Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, Arnold M, Erte I, Forgetta V, Yang TP, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014;46(6):543–50.CrossRefPubMedPubMedCentral
25.
go back to reference Zhao JV, Kwok MK, Schooling CM. Effect of glutamate and aspartate on ischemic heart disease, blood pressure, and diabetes: a mendelian randomization study. Am J Clin Nutr. 2019;109(4):1197–206.CrossRefPubMed Zhao JV, Kwok MK, Schooling CM. Effect of glutamate and aspartate on ischemic heart disease, blood pressure, and diabetes: a mendelian randomization study. Am J Clin Nutr. 2019;109(4):1197–206.CrossRefPubMed
26.
go back to reference Zhou K, Zhu L, Chen N, Huang G, Feng G, Wu Q, Wei X, Gou X. Causal associations between schizophrenia and cancers risk: a mendelian randomization study. Front Oncol. 2023;13:1258015.CrossRefPubMedPubMedCentral Zhou K, Zhu L, Chen N, Huang G, Feng G, Wu Q, Wei X, Gou X. Causal associations between schizophrenia and cancers risk: a mendelian randomization study. Front Oncol. 2023;13:1258015.CrossRefPubMedPubMedCentral
27.
go back to reference Zapata RC, Rosenthal SB, Fisch K, Dao K, Jain M, Osborn O. Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain. Sci Rep. 2020;10(1):18581.CrossRefPubMedPubMedCentral Zapata RC, Rosenthal SB, Fisch K, Dao K, Jain M, Osborn O. Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain. Sci Rep. 2020;10(1):18581.CrossRefPubMedPubMedCentral
28.
go back to reference Parksepp M, Leppik L, Koch K, Uppin K, Kangro R, Haring L, Vasar E, Zilmer M. Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease. Sci Rep. 2020;10(1):13983.CrossRefPubMedPubMedCentral Parksepp M, Leppik L, Koch K, Uppin K, Kangro R, Haring L, Vasar E, Zilmer M. Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease. Sci Rep. 2020;10(1):13983.CrossRefPubMedPubMedCentral
29.
go back to reference Rao ML, Gross G, Strebel B, Bräunig P, Huber G, Klosterkötter J. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res. 1990;34(3):243–57.CrossRefPubMed Rao ML, Gross G, Strebel B, Bräunig P, Huber G, Klosterkötter J. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res. 1990;34(3):243–57.CrossRefPubMed
30.
go back to reference Errico F, D’Argenio V, Sforazzini F, Iasevoli F, Squillace M, Guerri G, Napolitano F, Angrisano T, Di Maio A, Keller S, et al. A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. Transl Psychiatry. 2015;5(2):e512.CrossRefPubMedPubMedCentral Errico F, D’Argenio V, Sforazzini F, Iasevoli F, Squillace M, Guerri G, Napolitano F, Angrisano T, Di Maio A, Keller S, et al. A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. Transl Psychiatry. 2015;5(2):e512.CrossRefPubMedPubMedCentral
31.
go back to reference Nuzzo T, Sacchi S, Errico F, Keller S, Palumbo O, Florio E, Punzo D, Napolitano F, Copetti M, Carella M, et al. Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients. NPJ Schizophr. 2017;3:16.CrossRefPubMedPubMedCentral Nuzzo T, Sacchi S, Errico F, Keller S, Palumbo O, Florio E, Punzo D, Napolitano F, Copetti M, Carella M, et al. Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients. NPJ Schizophr. 2017;3:16.CrossRefPubMedPubMedCentral
32.
go back to reference Errico F, Rossi S, Napolitano F, Catuogno V, Topo E, Fisone G, D’Aniello A, Centonze D, Usiello A. D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801. J Neurosci. 2008;28(41):10404–14.CrossRefPubMedPubMedCentral Errico F, Rossi S, Napolitano F, Catuogno V, Topo E, Fisone G, D’Aniello A, Centonze D, Usiello A. D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801. J Neurosci. 2008;28(41):10404–14.CrossRefPubMedPubMedCentral
33.
go back to reference Nasyrova RF, Khasanova AK, Altynbekov KS, Asadullin AR, Markina EA, Gayduk AJ, Shipulin GA, Petrova MM, Shnayder NA. The role of D-Serine and D-aspartate in the pathogenesis and therapy of treatment-resistant schizophrenia. Nutrients. 2022;14(23):5142.CrossRefPubMedPubMedCentral Nasyrova RF, Khasanova AK, Altynbekov KS, Asadullin AR, Markina EA, Gayduk AJ, Shipulin GA, Petrova MM, Shnayder NA. The role of D-Serine and D-aspartate in the pathogenesis and therapy of treatment-resistant schizophrenia. Nutrients. 2022;14(23):5142.CrossRefPubMedPubMedCentral
34.
go back to reference Hao D, Liu C. Deepening insights into food and medicine continuum within the context of pharmacophylogeny. Chin Herb Med. 2023;15(1):1–2.PubMed Hao D, Liu C. Deepening insights into food and medicine continuum within the context of pharmacophylogeny. Chin Herb Med. 2023;15(1):1–2.PubMed
35.
go back to reference Zhang Y. Awareness and ability of paradigm shift are needed for research on dominant diseases of TCM. Chin Herb Med. 2023;15(4):475.PubMedPubMedCentral Zhang Y. Awareness and ability of paradigm shift are needed for research on dominant diseases of TCM. Chin Herb Med. 2023;15(4):475.PubMedPubMedCentral
36.
Metadata
Title
Asparagine reduces the risk of schizophrenia: a bidirectional two-sample mendelian randomization study of aspartate, asparagine and schizophrenia
Authors
Huang-Hui Liu
Yao Gao
Dan Xu
Xin-Zhe Du
Si-Meng Wei
Jian-Zhen Hu
Yong Xu
Liu Sha
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Schizophrenia
Published in
BMC Psychiatry / Issue 1/2024
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-024-05765-5

Other articles of this Issue 1/2024

BMC Psychiatry 1/2024 Go to the issue